INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
August 05, 2021 08:15 ET
|
INmune Bio, Inc.
LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update
August 04, 2021 16:20 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
July 28, 2021 16:05 ET
|
INmune Bio, Inc.
Management to host conference call at 4:30 pm ET on that day BOCA RATON, Florida, July 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology...
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data
July 26, 2021 08:30 ET
|
INmune Bio, Inc.
Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer’s disease and biomarkers of inflammation. Additional analysis...
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021
July 19, 2021 08:30 ET
|
INmune Bio, Inc.
Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer’s disease, which is expected to commence this year Boca Raton, FL, July 19, 2021 (GLOBE NEWSWIRE) --...
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING
July 14, 2021 09:02 ET
|
INmune Bio, Inc.
Boca Raton, FL., July 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)
July 12, 2021 08:00 ET
|
INmune Bio, Inc.
Boca Raton, FL, July 12, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
June 14, 2021 16:01 ET
|
INmune Bio, Inc.
Purchase of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock dilution upon execution. LA JOLLA, Calif, June 14, 2021 (GLOBE NEWSWIRE) -- ...
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN
June 02, 2021 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif, June 02, 2021 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
May 24, 2021 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, Calif, May 24, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...